193 related articles for article (PubMed ID: 30519041)
1. Long noncoding RNA H19 mediated the chemosensitivity of breast cancer cells via Wnt pathway and EMT process.
Gao H; Hao G; Sun Y; Li L; Wang Y
Onco Targets Ther; 2018; 11():8001-8012. PubMed ID: 30519041
[TBL] [Abstract][Full Text] [Related]
2. The long noncoding RNA H19 promotes tamoxifen resistance in breast cancer via autophagy.
Wang J; Xie S; Yang J; Xiong H; Jia Y; Zhou Y; Chen Y; Ying X; Chen C; Ye C; Wang L; Zhou J
J Hematol Oncol; 2019 Jul; 12(1):81. PubMed ID: 31340867
[TBL] [Abstract][Full Text] [Related]
3. Long Non-Coding RNA H19 Acts as an Estrogen Receptor Modulator that is Required for Endocrine Therapy Resistance in ER+ Breast Cancer Cells.
Basak P; Chatterjee S; Bhat V; Su A; Jin H; Lee-Wing V; Liu Q; Hu P; Murphy LC; Raouf A
Cell Physiol Biochem; 2018; 51(4):1518-1532. PubMed ID: 30497079
[TBL] [Abstract][Full Text] [Related]
4. Long noncoding RNA H19 acts as a miR-340-3p sponge to promote epithelial-mesenchymal transition by regulating YWHAZ expression in paclitaxel-resistant breast cancer cells.
Yan L; Yang S; Yue CX; Wei XY; Peng W; Dong ZY; Xu HN; Chen SL; Wang WR; Chen CJ; Yang QL
Environ Toxicol; 2020 Sep; 35(9):1015-1028. PubMed ID: 32420678
[TBL] [Abstract][Full Text] [Related]
5. LncRNA H19 promotes the development of hepatitis B related hepatocellular carcinoma through regulating microRNA-22 via EMT pathway.
Li L; Han T; Liu K; Lei CG; Wang ZC; Shi GJ
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5392-5401. PubMed ID: 31298392
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of Long Non-Coding RNA UCA1 Increases the Tamoxifen Sensitivity of Breast Cancer Cells through Inhibition of Wnt/β-Catenin Pathway.
Liu H; Wang G; Yang L; Qu J; Yang Z; Zhou X
PLoS One; 2016; 11(12):e0168406. PubMed ID: 27977766
[TBL] [Abstract][Full Text] [Related]
7. Curcumin attenuates lncRNA H19‑induced epithelial‑mesenchymal transition in tamoxifen‑resistant breast cancer cells.
Cai J; Sun H; Zheng B; Xie M; Xu C; Zhang G; Huang X; Zhuang J
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33179087
[TBL] [Abstract][Full Text] [Related]
8. Knockdown of lncRNA H19 restores chemo-sensitivity in paclitaxel-resistant triple-negative breast cancer through triggering apoptosis and regulating Akt signaling pathway.
Han J; Han B; Wu X; Hao J; Dong X; Shen Q; Pang H
Toxicol Appl Pharmacol; 2018 Nov; 359():55-61. PubMed ID: 30244121
[TBL] [Abstract][Full Text] [Related]
9. LncRNA LINP1 confers tamoxifen resistance and negatively regulated by ER signaling in breast cancer.
Ma T; Liang Y; Li Y; Song X; Zhang N; Li X; Chen B; Zhao W; Wang L; Yang Q
Cell Signal; 2020 Apr; 68():109536. PubMed ID: 31927036
[TBL] [Abstract][Full Text] [Related]
10. H19 lncRNA mediates 17β-estradiol-induced cell proliferation in MCF-7 breast cancer cells.
Sun H; Wang G; Peng Y; Zeng Y; Zhu QN; Li TL; Cai JQ; Zhou HH; Zhu YS
Oncol Rep; 2015 Jun; 33(6):3045-52. PubMed ID: 25846769
[TBL] [Abstract][Full Text] [Related]
11. LncRNA H19 promotes triple-negative breast cancer cells invasion and metastasis through the p53/TNFAIP8 pathway.
Li Y; Ma HY; Hu XW; Qu YY; Wen X; Zhang Y; Xu QY
Cancer Cell Int; 2020; 20():200. PubMed ID: 32514245
[TBL] [Abstract][Full Text] [Related]
12. HDAC2 inhibits EMT-mediated cancer metastasis by downregulating the long noncoding RNA H19 in colorectal cancer.
Hu XT; Xing W; Zhao RS; Tan Y; Wu XF; Ao LQ; Li Z; Yao MW; Yuan M; Guo W; Li SZ; Yu J; Ao X; Xu X
J Exp Clin Cancer Res; 2020 Dec; 39(1):270. PubMed ID: 33267897
[TBL] [Abstract][Full Text] [Related]
13. The Wnt signalling pathway is upregulated in an in vitro model of acquired tamoxifen resistant breast cancer.
Loh YN; Hedditch EL; Baker LA; Jary E; Ward RL; Ford CE
BMC Cancer; 2013 Apr; 13():174. PubMed ID: 23547709
[TBL] [Abstract][Full Text] [Related]
14. Long non-coding RNA H19 regulates proliferation and doxorubicin resistance in MCF-7 cells by targeting PARP1.
Wang Y; Zhou P; Li P; Yang F; Gao XQ
Bioengineered; 2020 Dec; 11(1):536-546. PubMed ID: 32345117
[TBL] [Abstract][Full Text] [Related]
15. LncRNA H19 is a major mediator of doxorubicin chemoresistance in breast cancer cells through a cullin4A-MDR1 pathway.
Zhu QN; Wang G; Guo Y; Peng Y; Zhang R; Deng JL; Li ZX; Zhu YS
Oncotarget; 2017 Nov; 8(54):91990-92003. PubMed ID: 29190892
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of lncRNA H19 sensitizes melanoma cells to cisplatin by regulating the miR-18b/IGF1 axis.
An LF; Huang JW; Han X; Wang J
Anticancer Drugs; 2020 Jun; 31(5):473-482. PubMed ID: 32265386
[TBL] [Abstract][Full Text] [Related]
17. Long non-coding RNA H19 mediates ovarian cancer cell cisplatin-resistance and migration during EMT.
Wu Y; Zhou Y; He J; Sun H; Jin Z
Int J Clin Exp Pathol; 2019; 12(7):2506-2515. PubMed ID: 31934077
[TBL] [Abstract][Full Text] [Related]
18. Long non-coding RNA H19 mediates N-acetyltransferase 1 gene methylation in the development of tamoxifen resistance in breast cancer.
Sun H; Wang G; Cai J; Wei X; Zeng Y; Peng Y; Zhuang J
Exp Ther Med; 2022 Jan; 23(1):12. PubMed ID: 34815764
[TBL] [Abstract][Full Text] [Related]
19. Silencing long non-coding RNA H19 combined with paclitaxel inhibits nasopharyngeal carcinoma progression.
Zhu H
Int J Pediatr Otorhinolaryngol; 2020 Nov; 138():110249. PubMed ID: 32736275
[TBL] [Abstract][Full Text] [Related]
20. Long non-coding RNA H19 is responsible for the progression of lung adenocarcinoma by mediating methylation-dependent repression of CDH1 promoter.
Gao LM; Xu SF; Zheng Y; Wang P; Zhang L; Shi SS; Wu T; Li Y; Zhao J; Tian Q; Yin XB; Zheng L
J Cell Mol Med; 2019 Sep; 23(9):6411-6428. PubMed ID: 31317666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
